NTLA
Intellia Therapeutics Inc

14,227
Mkt Cap
$1.45B
Volume
5.75M
52W High
$28.25
52W Low
$5.90
PE Ratio
-2.93
NTLA Fundamentals
Price
$12.50
Prev Close
$11.87
Open
$11.88
50D MA
$9.58
Beta
1.73
Avg. Volume
3.5M
EPS (Annual)
-$5.25
P/B
1.93
Rev/Employee
$143,615.39
Loading...
Loading...
News
all
press releases
Intellia Therapeutics (NASDAQ:NTLA) Downgraded to Sell Rating by Wall Street Zen
Wall Street Zen cut shares of Intellia Therapeutics from a "hold" rating to a "sell" rating in a report on Sunday...
MarketBeat·6h ago
News Placeholder
More News
News Placeholder
Sumitomo Mitsui Trust Group Inc. Sells 316,409 Shares of Intellia Therapeutics, Inc. $NTLA
Sumitomo Mitsui Trust Group Inc. decreased its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 11.8% in the 3rd quarter, according to the company in its most recent 13F filing...
MarketBeat·2d ago
News Placeholder
Nasdaq, S&P 500 Futures Edge Higher Ahead Of Long Weekend: Why NVDA, MU, NTLA, ASTS Are On Traders' Radar Today
Retail sentiment on Stocktwits remains bullish on the S&P 500, even as macro risks linger.
Stocktwits·2d ago
News Placeholder
Cathie Wood’s ARK Made Just One Buy Last Session — And It’s A Biotech Stock Up Nearly 30% YTD
ARK doubles down on a CRISPR bet as Intellia Therapeutics’ stock heads for its best week since October.
Stocktwits·2d ago
News Placeholder
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Average Recommendation of "Hold" from Brokerages
Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) has been given a consensus rating of "Hold" by the twenty-two ratings firms that are currently covering the firm, Marketbeat reports. Three...
MarketBeat·3d ago
News Placeholder
Intellia Therapeutics, Inc. (NTLA) Recently Broke Out Above the 200-Day Moving Average
Should investors be excited or worried when a stock crosses above the 200-day simple moving average?
Zacks·4d ago
News Placeholder
Intellia CEO Sells $314K in Stock While Holding Over 1 Million Shares
Key PointsThe president and CEO of Intellia Therapeutics sold 34,146 directly held shares of the firm on Jan. 5...
Nasdaq News: Markets·6d ago
News Placeholder
Intellia Therapeutics (NASDAQ:NTLA) Shares Gap Up - Time to Buy?
Intellia Therapeutics (NASDAQ:NTLA) Shares Gap Up - What's Next...
MarketBeat·10d ago
News Placeholder
Intellia Stock Declines Around 55% in 3 Months: Here's Why
NTLA shares plunge 55% in three months after the FDA placed a clinical hold on Nex-Z, suspending trials and milestone guidance following the death of a patient.
Zacks·13d ago
News Placeholder
Cathie Wood shells out $1.3 million on biotech stock
On the final trading day of 2025, Cathie Wood put an eye-brow raising $1.33 million to work in Intellia Therapeutics (NTLA), scooping up 145,153 shares in the gene-editing play. For the most part, it...
TheStreet.com·18d ago
<
1
2
...
>

Latest NTLA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.